Physician profile
James Brennan
NPI 1477533933
$2,655.69
in general payments reported to CMS, 2019-2025
27 companies · $55.28 in 2025
The $55.28 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,758 · 2020: $466 · 2021: $289 · 2022: $43.72 · 2024: $43.04 · 2025: $55.28.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $98.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $98.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $428.69 | 2019-2021 | |
| Novo Nordisk INC | $314.73 | 2019-2020 | |
| Medtronic Minimed, INC. | $196.09 | 2019-2020 | |
| Insulet Corporation | $157.19 | 2019-2021 | |
| Ibsa Pharma INC. | $139.88 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $133.38 | 2019-2021 | |
| Abbvie INC. | $126.16 | 2019-2022 | |
| Mannkind Corporation | $123.28 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $113.00 | 2019-2024 | Unithroid |
| Amgen INC. | $99.48 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $95.88 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $79.70 | 2019-2021 | |
| Valeritas, INC. | $75.07 | 2019 | |
| Lifescan, INC. | $72.52 | 2019-2021 | |
| Radius Health, INC. | $67.54 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $57.54 | 2019 | |
| Recordati_rare_diseases_inc. | $55.28 | 2025 | Isturisa |
| Merck Sharp & Dohme LLC | $52.91 | 2019-2021 | |
| Abbott Laboratories | $44.26 | 2019-2021 | |
| Tandem Diabetes Care, INC. | $42.25 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $41.19 | 2019-2020 | |
| Shire North American Group INC | $38.37 | 2019 | |
| Horizon Therapeutics Plc | $29.43 | 2020-2021 | |
| Ipsen Biopharmaceuticals, INC | $29.27 | 2020 | |
| Pfizer INC. | $15.77 | 2019 | |
| Roche Diabetes Care, INC. | $14.00 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $12.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brennan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.